Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Liver Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/23/2019 |
| Start Date: | January 30, 2014 |
| End Date: | December 31, 2020 |
PET/CT-Derived Hepatopulmonary Shunt Fraction Following Yttrium-90 Radioembolization
This pilot clinical trial studies positron emission tomography (PET)/computed tomography (CT)
in finding beads after Yttrium-90 bead therapy in patients with primary liver cancer or
cancer that has spread to the liver (metastatic) that can not be removed by surgery. Imaging
procedures, such as PET/CT after Yttrium-90 bead therapy, may help see if the beads are
present in the lung and compare the results with the pre-therapy imaging.
in finding beads after Yttrium-90 bead therapy in patients with primary liver cancer or
cancer that has spread to the liver (metastatic) that can not be removed by surgery. Imaging
procedures, such as PET/CT after Yttrium-90 bead therapy, may help see if the beads are
present in the lung and compare the results with the pre-therapy imaging.
PRIMARY OBJECTIVES:
I. To estimate the absolute difference in post-therapy Yttrium-90 microsphere hepatopulmonary
shunt fraction and the pre-therapy Technetium-99m macroaggregated albumin hepatopulmonary
shunt fraction in patients with unresectable primary hepatic malignancy and hepatic
metastatic disease.
SECONDARY OBJECTIVES:
I. To quantify and compare the pre-therapy Technetium-99m macroaggregated albumin particle
sizes and post-therapy Yttrium-90 microsphere sizes.
OUTLINE:
Patients receive routine pre-therapy Technetium-99m macroaggregated albumin. Patients then
undergo routine radioembolization with Yttrium-90 microspheres. Within 36 hours after
radioembolization, patients undergo PET/CT imaging.
Available imaging, clinical, interventional and surgical follow-up data for 2 years after
completion of enrollment in the study will be obtained.
I. To estimate the absolute difference in post-therapy Yttrium-90 microsphere hepatopulmonary
shunt fraction and the pre-therapy Technetium-99m macroaggregated albumin hepatopulmonary
shunt fraction in patients with unresectable primary hepatic malignancy and hepatic
metastatic disease.
SECONDARY OBJECTIVES:
I. To quantify and compare the pre-therapy Technetium-99m macroaggregated albumin particle
sizes and post-therapy Yttrium-90 microsphere sizes.
OUTLINE:
Patients receive routine pre-therapy Technetium-99m macroaggregated albumin. Patients then
undergo routine radioembolization with Yttrium-90 microspheres. Within 36 hours after
radioembolization, patients undergo PET/CT imaging.
Available imaging, clinical, interventional and surgical follow-up data for 2 years after
completion of enrollment in the study will be obtained.
Inclusion Criteria:
- Patients who undergo intra-arterial hepatic 99mTc MAA evaluation in anticipation of
90Y microsphere radioembolization
Exclusion Criteria:
- Patients who are unable to give consent
- Prisoners
We found this trial at
1
site
300 W 10th Ave
Columbus, Ohio 43210
Columbus, Ohio 43210
(800) 293-5066
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center...
Click here to add this to my saved trials
